Found: 3
Select item for more details and to access through your institution.
Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem™).
- Published in:
- 2017
- By:
- Publication type:
- journal article
P3‐003: 11‐β HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS: PRECLINICAL AND CLINICAL SYSTEMATIC REVIEWS.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P926, doi. 10.1016/j.jalz.2019.06.3029
- By:
- Publication type:
- Article
XANAMEMTM: A NOVEL 11B-HSD1 INHIBITOR WITH POTENTIAL TO PROVIDE DURABLE SYMPTOMATIC AND DISEASE MODIFYING BENEFITS IN ALZHEIMER’S DISEASE.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2016, v. 12, p. P1186, doi. 10.1016/j.jalz.2016.07.133
- By:
- Publication type:
- Article